Treatment News : Ambivalence About Generic Meds Reigns in the UK

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » June 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


June 18, 2013

Ambivalence About Generic Meds Reigns in the UK

A recent poll of people with HIV living in the United Kingdom found that they largely understood the financial importance of shifting to generic antiretrovirals (ARVs) in the coming years, and that they also expressed significant reservations about how the drugs would affect efficacy, pill burden and side effects, aidsmap reports. Conducted by NAM during April and May 2013, the confidential online survey polled 122 people with HIV in the United Kingdom. A total of 110 of the respondents were male, and the group had an average age of 42.

During the next few years, many of the top HIV medications will go off patent in that country. Equivalents of the core components of Atripla will soon be available in generic from in the United States.

Nearly nine in 10 of the respondents knew what a generic drug was, and 70 percent believed such a drug would provide a better value than a brand-name drug.

A total of 45 percent of the respondents said they would consider it annoying, confusing, inconvenient or concerning if their care provider asked them to switch from a brand-name to a generic antiretroviral. Sixty-eight percent were concerned about changes in efficacy, and 65 percent about side effects. Fifty-six percent were concerned with the methods required to take their drug regimen, including the potential for increased pill burden or food restrictions.

To read the aidsmap story, click here.

To download a copy of the poster presentation on the poll, click here.

Search: generics, antiretrovirals, ARVs, HIV, United Kingdom, NAM, aidsmap, Atrpila.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.